

# **TKA Arthroplasty: Optimization and Outcomes**

**Marc DeHart, MD**

**Adult Hip and Knee Reconstruction**



**Certificate of Added Qualification in Sports Medicine**

**Associate Professor Dept. of Orthopaedic Surgery**

**UT Health San Antonio**

# Disclosures:

- Organized Medicine:
  - Texas Orthopaedic Association
  - Presidential Line & Board Position
  - American Academy Orthopaedic Surgeons
  - Board of Councilors
  - CMS Rep for **Quality Measures**
  - CMS Committees for **Cost Measures**
- Editorial Review Board:
  - Journal of Arthroplasty
- \$:
  - Orthopaedic Board and MOC Review Courses
  - Co-Director of Saudi Board Review Course
  - Chapters for Orthopaedic Books



- **Outcomes: Why now?**
- **What is optimization?**
- **Is it working?**

# Outcomes why now?

## Why did you become a PA?



# We go into medicine because:

- Intellectually challenging
- Fairly well respected
- Secure job
- Science and Art
- Desire to help people
  - Decrease suffering**
  - Save lives**
- Rewarding profession
  - Ethically
  - Economically




# Buddhism: 1<sup>st</sup> Noble Truth

**Life is suffering**

- **Human Condition:**
  - Sickness**
  - Aging**
  - Death**


**Fasting  
Buddha**




# We can make a difference...

## Miracles of Medicine

- Ophthalmology:  
blind to see



Mature Cataract



One day post-op Extracap


- ENT: deaf to hear



# We can make a difference...

## Miracles of Medicine

- Psychiatry:  
calm the demons
- Public Health: cure plagues



Measles in 2019



# We can make a difference...

## Miracles of Medicine

The Raising of Lazarus ~ Rembrandt



- **Cardiology: raise the dead**

- **Ortho: lame to walk**



Why did we go into medicine?

**Paid to MAKE A DIFFERENCE**



# The Most And Least Meaningful Occupations

1 of 20



**No. 1 Most Meaningful Job (tie):  
Orthopedic Surgeon**

% High Job Meaning: 100%  
% Male: 88%  
% Female: 12%

**Forbes**<sup>®</sup>  
M A G A Z I N E



## THE MOST FEEL-GOOD JOBS IN AMERICA

17) Physician Assistants



**PERCENT FEEL THEIR JOB MAKES THE WORLD BETTER:  
97.1%**


**•We make a difference!**

# Do we all make the same difference?

## Substantial Variation

# TKA/1,000 Medicare Enrollees  
~4 in Hawaii to 15 in Idaho!

(Dartmouth atlas)




# Variation by Doctor (Orthopaedic)

- Specific provider behavior:
- Per patient data  
(to remove volume data)

# services per patient  
\$ spent per patient

- Austin, Texas 2013




# Variation by Doctor (Orthopaedic)

- Specific provider behavior:
- Per patient data  
(to remove volume data)

# services per patient  
\$ spent per patient

- Austin, Texas 2013




Huge variation in the costs we create  
for the differences we make...

# POLICY MAKERS AND PAYERS HAVE DECLARED WAR ON VARIATION

---

Regional Variation in Medicare Spending per Beneficiary




# Musculoskeletal Spend is: High on the list

## COSTS HAVE INCREASED FOR MANY REASONS

- Technology > Evidence base
- Pts: Older/sicker/fatter
- 3<sup>rd</sup> party payers = ↓ personal costs
- Poor understanding of costs/benefits by Pt & Clinicians
- Corporatization of medicine
- System rewards for volume (FFS)

Per capita expenditures in US \$ by disease category, 2000 - 2013




Note: Expenditures on nursing home and dental care are not included in health services spending by disease.

Source: Kaiser Family Foundation analysis of the Bureau of Economic Analysis Health Care Satellite Account (Blended Account). Accessed January 25, 2016. • [Get the data](#) • [PNG](#)



**Figure.** Proposed “Wedges” Model for US Health Care, With Theoretical Spending Reduction Targets for 6 Categories of Waste




# COSTS HAVE INCREASED FOR MANY REASONS

- Technology > Evidence base
- Pts: Older/sicker/fatter
- 3<sup>rd</sup> party payers = ↓ personal costs
- Poor understanding of costs/benefits by Pt & Clinicians
- Corporatization of medicine
- System rewards for volume (FFS)

The “wedges” model for US health care follows the approach based on the model by Pacala and Socolow.<sup>9</sup> The solid black “business as usual” line depicts a current projection of health care spending, which is estimated to grow faster than the gross domestic product (GDP), increasing the percentage of GDP spent on health care; the dashed line depicts a more sustainable level of health care spending growth that matches GDP growth, fixing the percentage of GDP spent on health care at 2011 levels. Between these lines lies the “stabilization triangle”—the reduction in national health care expenditures needed to close the gap. The 6 colored regions filling the triangle show one possible set of spending reduction targets; each region represents health care expenditures as a percentage of GDP that could be eliminated by reduction of spending in that waste category over time.

# Growth of Physicians and Administrators 1970-2009



**2300% increase in U.S. healthcare spending per capita between 1970-2009.**


Source: *Health Care Costs: A Primer*, The Henry J. Kaiser Family Foundation.

Source: Bureau of Labor Statistics; NCHS; and Himmelstein/Woolhandler analysis of CPS.


1965  
Medicare

Since Medicare started, a growing % of Federal spending on health care...


So high now = a threat for spending on:  
Infrastructure  
Education  
Defense



**1965**  
Medicare




Increasing costs lead to many laws to “improve” payment systems...




1965  
Medicare

# Balance Budget Amendment Sustainable Growth Rate (all care allowed but divided the pie)



**SGR – (from the Balanced Budget Amendment)**  
**“fixed the total costs” and the dollars per RVU came down**




**Inflation ~ +3%**

**TKA ~ -60%**

**Fig. 1** The Consumer Price Index, an inflationary indicator, has continued to increase since 1992 while reimbursements for orthopaedic procedures have declined, creating an ever-widening gap between what orthopaedic surgeons receive in reimbursements and what they have to pay in operational and practice costs.

# As reimbursements go down, the fee for service system responds by increasing volume...



Note: E&M (evaluation and management). Volume growth for E&M from 2009 to 2010 is not directly observable due to a change in payment policy for consultations. To compute cumulative volume growth for E&M through 2011, we used a growth rate for 2009 to 2010 of 1.85 percent, which is the average of the 2008 to 2009 growth rate of 1.70 percent and the 2010 to 2011 growth rate of 2.00 percent.

Source: MedPAC analysis of claims data for 100 percent of Medicare beneficiaries.



- ↑ Physician owned ancillaries
- ↑ MRIs
- ↑ ASCs
- ↑ Procedures

**Problems with pay for volume?**






**Figure 1.** The Law of Diminishing Returns

Benefit = Quality  
comes Out

Inputs = Volume  
(Costs)  
(Profits  
)




The first unit of input provides substantial benefits (imagine the first physician in a community), while additional units provide declining additional benefit (imagine the thousandth physician). Eventually, increasing inputs lead to no additional benefit (the “flat of the curve”). At some point, in theory, additional inputs lead to harm.

**Figure 1.** The Law of Diminishing Returns

Benefit = Quality  
comes Out

Inputs = Volume (Costs)  
(Profits)




**At some point:  
for the dollars spent,  
we get no more  
benefit...  
...and cause harm**

**Figure 1.** The Law of Diminishing Returns

Benefit = Quality  
comes Out

Inputs = Volume (Costs)  
(Profits)




**The problem is:  
we don't know where we  
are on the curve.**

**Figure 1.** The Law of Diminishing Returns

Benefit = Quality  
comes Out

Inputs = Volume (Costs)  
(Profits)



## Profits not tied to outcomes

There is as much profit/unit (or more) from causing harm  
Very little profit from prevention

**In “Ideal Insurance” –  
Patients would pay by outcome.  
Arrow 1963**

**Kenneth Arrow  
Youngest Winner  
1972 Nobel Prize in Economics**





# Problems with pay for volume?

Indications have expanded and as we have included less severe knees, we have had less improvement for the spend...


Impact of total knee replacement practice: cost effectiveness analysis of data from the Osteoarthritis Initiative

Bart S Ferket,<sup>1</sup> Zachary Feldman,<sup>2</sup> Jing Zhou,<sup>1</sup> Edwin H Oei,<sup>3</sup> Sita M A Bierma-Zeinstra,<sup>4,5</sup> Madhu Mazumdar<sup>1</sup>

### Proposed eligibility for total knee replacement (ICER \$/QALY)

× Current practice

- SF-12 PCS <55
- SF-12 PCS <50 (1 109 675)
- SF-12 PCS <45 (371 439)
- SF-12 PCS <40 (217 615)
- SF-12 PCS <35 (160 974)
- SF-12 PCS <30 (126 762)
- SF-12 PCS <25 (108 773)
- SF-12 PCS <20 (88 903)
- No surgery
- Not dominated



# Problems with pay for volume?




Impact of total knee replacement practice: cost effectiveness analysis of data from the Osteoarthritis Initiative

The practice of total knee replacement as performed in a recent US cohort of patients with knee osteoarthritis had minimal effects on QALYs at the group level and was found to be economically unattractive

Total knee replacement practice, however, could be considered cost effective if the procedure were restricted to patients with more severely affected functional status

Early – moderate arthritis is best managed nonoperatively



# Problems with pay for volume?

**Burn out: emotional exhaustion  
depersonalization  
fail to meet personal goals**

**Moral distress ~ when an individual  
feels that external or internal  
constraints preclude the performance  
of an ethically appropriate choice or  
action.**



Medscape



**National  
Physician  
Burnout,  
Depression  
& Suicide  
Report**

2019





# Problems with pay for volume?



Medscape

## National Physician Burnout, Depression & Suicide Report

2019



# Moral Injury

perpetrating, failing to prevent, bearing witness to, or learning about acts that transgress deeply held moral beliefs and expectations

Doing, failing to prevent, witnessing or learning about practices that violate your moral beliefs and expectations


<https://www.medicaleconomics.com/med-ec-blog/beyond-burnout-real-problem-facing-doctors-moral-injury>

Moral distress ~ when an individual feels that external or internal constraints preclude the performance of an ethically appropriate choice or action.

Moral distress ~ psychic pain we feel when we know we are about to make an unethical action.

1965  
Medicare


# ACA: “Obamacare”




2010  
PPACA  
"Obamacare"



- Access:  
Demand participation
- Medical loss ratio of no less than 85%
- No pre-existing conditions
- No lifetime caps
- Preventive health programs
- Value-Based programs:  
ACO  
Episode payment (bundles)




# The most bipartisan government in history finds something to agree on!




1965  
Medicare

# MACRA:



2015  
MACRA  
“SGR FIX”

MACRA:  
stabilize MD payments  
define quality program



[Home](#) > [Legislation](#) > [114th Congress](#) > H.R.2

Print Subscribe

## H.R.2 - Medicare Access and CHIP Reauthorization Act of 2015

114th Congress (2015-2016) | [Get alerts](#)

**BILL**


**Sponsor:** [Rep. Burgess, Michael C. \[R-TX-26\]](#) (Introduced 03/24/2015)

**Committees:** House - Agriculture; Budget; Energy and Commerce; Judiciary; Natural Resources; Ways and Means

**Latest Action:** 04/15/2015 Message on Senate action sent to the House.

**Major Recorded Votes:** 04/14/2015 : [Passed Senate](#); 03/26/2015 : [Passed House](#)

**Tracker:**




**“Nobody spends somebody else's money as carefully as he spends his own.”**

**Milton Friedman - Nobel Prize in Economics**






# “Value-based care: 2 ways to seek quality payments:



- **\$ Incentives:**
  - Quality Metrics**
  - Cost Metrics**

- **Financial risk + quality metrics:**
  - ACO**
  - Bundles**

# MACRA ~ “Pay for Value”



Source: CMS

# MACRA

- If we work to have better results and create higher value then get more \$





- If non-participator or if participate with no change and have low value:




# Michael Porter

## Harvard Economist


$$\text{VALUE} = \frac{\text{OUTCOME}}{\text{COST}}$$



# Outcomes





# Outcomes



# Outcomes

## Healthcare Quality Model Donabedian 1966



# Costs of Arthritis Care

## Non-operative/Community costs

- Conservative management costs
- Specialist evaluation costs
- Preparation/Optimization costs

## Hospital Costs:

- Implant cost – strategies to decrease
  - Price caps vs implant standardization
  - Group purchasing
  - Joint Registry ~ outcomes by component
  - Gain sharing

- Length of Stay
  - Surgical technique improvements
    - No drains
    - Tranexamic acid
    - Pain control ~ spinal/local injection
  - Clinical pathways/Joint camp
    - Expectations
    - Early PT

- Operating Room Costs - time
  - Efficient standardized teams
  - Be prepared – people and supplies
  - Start on time

## Post Acute Costs

- Self care vs Home PT vs Outpatient PT
- SNF vs Rehab

## Complication Costs

- Early 30 or 90 days
- Long term – revision/reoperation rates




# Cost outcome metrics

Acumen – CMS contracted

Crafting episode based cost metrics for everyone

Based exclusively on the claims you bill/collect

## Wave 3 CS Activities and Meetings, May – September 2019



# COST: (Claims data) already being benchmarked!

Specialist level use	Specialist level cost	Specialty comparison
$\left[ \left( \frac{\text{Mean work RVU per patient}}{\text{Mean patient RRS}} \right) \left( \frac{\text{Total paid}}{\text{Sum of total RVUs}} \right) \right] / [\text{Specialty efficiency score}]$		
RVU: relative value units; RRS: relative risk score		

**Figure 1** Specialist efficiency index formula

- **Michigan BCBS**
- **Specialist “cost efficiency reporting”  
to specialists and their referrers**
- **Orthopaedics - ↓ utilization by 13%**  
(without direct plan reward or consequences)

# TKA METRICS ~ 90 day costs


10% collected by providers

58% paid to hospitals

32% paid to **Post-Acute Care**  
 Home Discharges best  
 Unless problems that cause  
 readmissions

## National Distribution of Payments for Total Hip Arthroplasty/ Total Knee Arthroplasty (THA/TKA) 90-Day Episode of Care

Data Period: April 1, 2015 through March 31, 2018



### Legend

- 🏢 Index Facility
- 👨 Index Physician
- 🏠 Skilled Nursing Facility
- 🏢 Readmission Facility
- 🏠 Non-Acute Inpatient Settings
- 🏠 Other Outpatient Settings
- 🏠 Home Health Agency
- 👨 Readmission Physician
- 👨 Miscellaneous (ambulance, medical supplies, other)
- 👨 Outpatient Physician Visit
- 🏠 Hospice
- 🏢 Emergency Department
- 🏠 Observation Stay
- 🏠 Inpatient Rehabilitation
- 👨 Durable Medical Equipment
- 🏠 Outpatient Rehabilitation

# Readmissions are very costly

~ \$8,500

- **Joint Related**

91/325 ~1/3

- **Medical Issues**

234/325 ~2/3

Health Policy & Economics

## How Much Does a Readmission Cost the Bundle Following Primary Hip and Knee Arthroplasty?



Jessica L.H. Phillips, MD, Alexander J. Rondon, MD, MBA, Chris Vannello, RN, BSN, Yale A. Fillingham, MD, Matthew S. Austin, MD, P. Maxwell Courtney, MD<sup>\*</sup>

*Department of Orthopaedic Surgery, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA*

### Mean Claims Costs of Readmission by Reason Following THA and TKA.

Reason for Readmission	N	Mean Readmission Costs (SD)
Periprosthetic joint infection	40	\$11,952 (\$5988)
Periprosthetic fracture	14	\$16,852 (\$6475)
Other revision surgery	14	\$17,263 (\$6146)
Venous thromboembolic event	23	\$6334 (\$2459)
Acute kidney injury	22	\$7040 (\$4658)
Cardiac event	40	\$9689 (\$10,926)
Gastrointestinal	38	\$5389 (\$2080)
Respiratory	17	\$8092 (\$5844)
Neurologic	32	\$5936 (\$2726)
Other medical pathology	53	\$6969 (\$4738)
Fever or cellulitis without any surgical intervention	32	\$7387 (\$3889)
Total	325	\$8560 (\$6511)

SD, standard deviation; THA, total hip arthroplasty; TKA, total knee arthroplasty.

# Easy Quality Outcomes metrics: “Claims Based”

**Post-op complications at 90 days**  
**Readmissions in 90 days**  
**Secondary procedures in 90 days**

**More important for long term: (FOR FUTURE PROGRAMS)**

**Did patient improve from preop?**  
**PROM ~ patient reported outcome measures**

**How much did patient improve from preop?**  
**PROM at 1 year**

**How long did improvement last before next surgery?**  
**Quality of life years**

**Quality Metrics:**  
**Joint Commission**



**THKR-1 Regional Anesthesia**

**THKR-2 Day #0 Postoperative Ambulation**

**THKR-3 Discharged to Home**

**THKR-4 Preoperative Functional/Health Status Assessment**

# Quality Metrics: AAHKS



# AAHKS<sup>®</sup>

AMERICAN ASSOCIATION OF  
HIP AND KNEE SURGEONS

- » Measure #1a-1c: Assessment of Patient Hx & PE, Radiographic Evidence of Arthritis
- » Measure #2: Shared Decision Making: Trial of Conservative (Non-surgical) Therapy
- » Measure #3: DVT/PE and Cardiac Risk Evaluation
- » Measure #4: Preop Antibiotic prior to Tourniquet
- » Measure #5: Identification of Implant in Op Report

Detailed Methodology for the 2018 Value Modifier and the 2016 QRUR

Exhibit B.4 (continued)

PQRS or QCDR Number (GPRO/eCQM Number)	Measure Name	Quality Domain
330*	Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days	Patient Safety
335	Maternity Care: Elective Delivery or Early Induction Without Medical Indication at $\geq 37$ and $< 39$ Weeks	Patient Safety
347*	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital	Patient Safety
348*	HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate	Patient Safety
351	Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation	Patient Safety
352	Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet	Patient Safety
353	Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report	Patient Safety
354*	Anastomotic Leak Intervention	Patient Safety
355*	Unplanned Reoperation Within the 30 Day Postoperative Period	Patient Safety



# Quality Metrics: National Quality Forum

“consensus based entity” recognized by US Congress

Public/Private partnership  
in 2008 expenses were \$18.8 Million (Feds pay \$14 million)

Reports annually to Congress and Health and Human Services  
via “Measure Applications Partnership” (MAP)

3 work groups: Hospital


Clinicians

Post-acute/Long-Term Care

Membership: patients, clinicians, providers, purchasers,  
payers

Endorses “Performance Measures”  
for both federal, public and private payers  
encourages alignment between payers ~ “harmonization”

Healthcare Sector	Percentage by Healthcare Sector
Provider	43%
Patient/Caregiver	1%
Consumer	4%
Health Professional	19%
Supplier/Industry	2%
Health Plan	6%
QMRI	6%
Health Agency	1%
Health Plan	6%
Public/ Community Health	4%
Public Health and Measurement Researcher (PHMR)	7%







# Quality Metrics: National Quality Forum

Healthcare Sector	Percentage by Healthcare Sector
Provider	43%
Patient/Caregiver	1%
Consumer	4%
Health Professional	19%
Supplier/Industry	2%
Health Plan	6%
QMRI	6%
Health Agency	1%
Health Plan	6%
Public/ Community Health	4%
Public Health and Measurement Researcher (PHMR)	7%


**Public/Private partnership “consensus based entity”**

**Reports to Congress**

**Membership: patients**

**clinicians  
providers  
purchasers  
payers**

**Endorses “Performance Measures”  
for both federal, public and private payers  
encourages alignment between payers ~ “harmonization”**



# Core Quality Measures Collaborative (Hosted by National Quality Forum)

**CMS** ~ Centers for Medicare & Medicaid Services

**AHIP** ~ America's Health Insurance Plans



1550 Hospital-level  
Risk-standardized **complication rate** (RSCR)  
Within **90 days after arthroplasty**

1551 Hospital-level  
(RSRR) All-cause risk-standardized **readmission rate**  
Within **30 days after arthroplasty**















1741 Patient Experience with Surgical Care Based on the  
Consumer Assessment of Healthcare Providers and Systems  
(CAHPS®) Surgical Care Survey

# Public Reporting

1550 Hospital-level  
Risk-standardized **complication rate (RSCR)**  
Within **90 days after arthroplasty**

1551 Hospital-level  
All-cause risk-standardized **readmission rate (RSRR)**  
Within **30 days after arthroplasty**

1741 Patient Experience with Surgical Care Based on the  
Consumer Assessment of Healthcare Providers and Systems  
(CAHPS®) Surgical Care Survey

	UNIVERSITY HEALTH SYSTEM 4502 MEDICAL DR SAN ANTONIO, TX 78229 (210) 358-2637 	METHODIST HOSPITAL 7700 FLOYD CURL DR SAN ANTONIO, TX 78229 (210) 575-4000 	NATIONAL RESULT
	<b>Overall rating</b>  <a href="#">Learn more</a> <b>Distance</b>  : 0.2 miles <a href="#">Add to My Favorites</a> <a href="#">Maps and directions</a>	<b>Overall rating</b>  <a href="#">Learn more</a> <b>Distance</b>  : 0.4 miles <a href="#">Add to My Favorites</a> <a href="#">Maps and directions</a>	
Rate of complications for hip/knee replacement patients	No Different Than the National Rate	Worse Than the National Rate	2.5%
	<b>Overall rating</b>  <a href="#">Learn more</a> <b>Distance</b>  : 0.2 miles <a href="#">Add to My Favorites</a> <a href="#">Maps and directions</a>	<b>Overall rating</b>  <a href="#">Learn more</a> <b>Distance</b>  : 0.4 miles <a href="#">Add to My Favorites</a> <a href="#">Maps and directions</a>	
Rate of readmission after hip/knee replacement	No Different Than the National Rate	No Different Than the National Rate	4%
	<b>Overall rating</b>  <a href="#">Learn more</a> <b>Distance</b>  : 0.2 miles <a href="#">Add to My Favorites</a> <a href="#">Maps and directions</a>	<b>Overall rating</b>  <a href="#">Learn more</a> <b>Distance</b>  : 0.4 miles <a href="#">Add to My Favorites</a> <a href="#">Maps and directions</a>	
Payment for hip/knee replacement patients	No Different Than the National Average Payment	Greater Than the National Average Payment	\$21,392




<http://www.qualitynet.org>

CMS-approved website for secure communications and healthcare quality data


**WHERE TO FIND YOUR DATA**

### 2019 Procedure-Specific Complication Measure Updates and Specifications Report

Figure 4.2.2 – Distribution of Hospital THA/TKA RSCRs between April 2015 and March 2018



### 2019 Procedure-Specific Readmission Measures Updates and Specifications Report



# How to affect Outcomes:

## Preoperative Risk Factors

## Intra-operative Risk Factors

## Postoperative Risk Factors

### Surgical Risk Reduction Toolkit



The intent of the Surgical Risk Reduction Toolkit is to provide physicians with strategies to mitigate risk factors that have been demonstrated to contribute to complications. This toolkit includes:

- A full review of major surgical risk factors
- A temporal approach to addressing risk factors – preoperative, intra-operative, postoperative
- Multilayered content stating general information and delving into deeper detail with guides to help reduce risk

This guide will have a positive effect on orthopaedic practice, patients' preoperative and overall health, reduce complication rates and help surgeons ensure the best possible outcomes

#### Preoperative Risk Factors

Optimize your patients' preoperative risk factors (e.g., nutrition, diabetes, depression, etc.) to reduce postoperative complications and improve outcomes.

[LEARN MORE](#)



#### Intraoperative Risk Factors

Be prepared and have a plan to address critical situations during surgery.

[LEARN MORE](#)




#### Postoperative Risk Factors

Address critical postoperative risk factors (e.g., blood mgmt.) and prepare patients for recovery and discharge.

[LEARN MORE](#)



# Preoperative Risk Factors



## “Patient Optimization”

## Surgical Risk Reduction Toolkit



The intent of the Surgical Risk Reduction Toolkit is to provide physicians with strategies to mitigate risk factors that have been demonstrated to contribute to complications. This toolkit includes:

- A full review of major surgical risk factors
- A temporal approach to addressing risk factors – preoperative, intra-operative, postoperative
- Multilayered content stating general information and delving into deeper detail with guides to help reduce risk

This guide will have a positive effect on orthopaedic practice, patients' preoperative and overall health, reduce complication rates and help surgeons ensure the best possible outcomes

### Preoperative Risk Factors

Optimize your patients' preoperative risk factors (e.g., nutrition, diabetes, depression, etc.) to reduce postoperative complications and improve outcomes.

[LEARN MORE](#)



### Intraoperative Risk Factors

Be prepared and have a plan to address critical situations during surgery.

[LEARN MORE](#)




### Postoperative Risk Factors

Address critical postoperative risk factors (e.g., blood mgmt.) and prepare patients for recovery and discharge.

[LEARN MORE](#)




# Seven Controllable Variables in Orthopaedic Surgery Patient Outcomes



# Optimization:

~making the best or most effective use of a situation or resource



- **Selecting patients**  
Where Benefits >> Risks  
To improve both patient and population health
- **Processes preparing**  
Minimize complications  
Improve chances for success
- **Compliance to guidelines**  
Consistency to see what works  
For best results  
For cost efficiency



# Optimization:



~making the best or most effective use of a situation or resource

Patient  
Selection

- **Selecting patients**

Where Benefits >> Risks

To improve both patient and population health



# Sites of Optimization:

Perioperative Surgical Home

Perioperative Enhancement Team (POET)

PASS clinic ~ perioperative anesthesia surgical screening

Preop Clinic

Medical Optimization Team

Joint Camps



# TEAM APPROACH: PERIOPERATIVE OPTIMIZATION FOR TOTAL JOINT ARTHROPLASTY

JBJS REVIEWS 2018;6(10):e4 • <http://dx.doi.org/10.2106/JBJS.RVW.17.00147>



We're One of the Best Hospitals in the Country and Ranked Top 5 for Orthopedics

	1	2	3
<b>Infection</b>	Not Applicable	Not Applicable	(+) MRSA - Decolonize (+) HIV - Viral load undetectable (+) HCV - Antiviral treatment/cure
<b>Smoking</b>	<b>History of Smoking</b> Enroll in Smoking Cessation Program 4 to 8 Weeks Prior to Surgery	Not Applicable	Not Applicable
<b>Obesity</b>	<b>BMI 30-34.9</b> Nutritional Counseling Program	<b>BMI 35-39.9</b> Nutritional Counseling + Acute Weight Loss Program	<b>BMI ≥ 40</b> Nutritional Counseling + Long-term Weight Loss +Bariatric Consult
<b>Cardiovascular Disease</b>	<b>History of CVD*</b> Enroll into cardiac optimization program	Not Applicable	Not Applicable
<b>Venous Thromboembolic Disease</b>	<b>VTE Risk Factors**</b>	<b>History of PE or DVT</b> IVC Filter or Aggressive VTE Management	Not Applicable
<b>Neurocognitive Psychological Behavioral</b>	Neurocognitive Deficits or ≥ 7 catastrophizing, PHQ-9	Alcohol Abuse or Chronic Active Narcotic Dependency	Not Applicable
<b>Physical Deconditioning</b>	Frailty or Physical Function/Ambulation	Nonambulatory or Requires Transfer Assistance	Not Applicable
<b>Diabetes</b>	Well Controlled	<b>HgbA1c ≥ 8</b> Refer to Endocrinologist	<b>Fasting Glucose &gt; 180 mg/dl</b> Must correct prior to surgery
<b>Risk Factor Subtotal</b>			<b>Total</b>

### Figure Legend

HARD STOP

Fig. 1

RRAT. Patients undergoing total joint arthroplasty may be risk-stratified for the risk of readmission using this tool. Modifiable risk factor categories are listed in the left column with their respective risk factors in the 3 adjacent columns. Risk factors are graded on the basis of severity (columns 1, 2, and 3) and the total score is summed. RRAT scores of ≥ 3 should result in a hard stop until the patient is optimized. The stop hand indicates a hard stop until the modifiable risk factor is resolved. A single asterisk indicates that the patient has a history of coronary artery disease, had had a cerebrovascular accident, has peripheral vascular disease, venous thromboembolic disease, at least 21 cardiac risk factors, renal insufficiency (creatinine clearance, <60 mL/min), diabetes, chronic obstructive pulmonary disease, hypertension, cancer, or heart failure; has an age of ≥ 60 years, and is a recent smoker (quit within <30 days). Two asterisks indicate that the patient has venous thromboembolic disease (VTE) risk factors: cerebrovascular accident, chronic obstructive pulmonary disease, BMI of ≥ 40 kg/m<sup>2</sup>, coronary artery disease, peripheral vascular disease, or thrombophilia (activated protein C resistance, elevated factor VIII and lipoprotein A). MRSA = methicillin-resistant *Staphylococcus aureus*; HIV = human immunodeficiency virus; HCV = hepatitis C virus; CVD = cardiovascular disease; PE = pulmonary embolism; DVT = deep venous thromboembolism; Hgb = hemoglobin, and IVC = inferior vena cava.



# Duke's Program: PASS

## Perioperative Anesthesia Surgical Screening Clinic

### Check List @ PASS clinic

#### Risk Stratification Checklist for Total Joint Replacement

- BMI  $\geq 40 \text{ kg/m}^2$
- Active smoking
- HgA1C  $>7.5\%$
- Albumin  $\leq 3 \text{ g/dL}$
- Hemoglobin  $< 11 \text{ g/dL}$
- Thrombocytopenia (platelets  $< 50\text{K/L}$ )
- ESRD on Dialysis
- CAD (with or without AMI in past 6 months)
- Stroke or TIA within past 6 months
- Active infections
- Chronic narcotics use (addiction)




### Referral Specialty Clinics for optimization when needed

# TKA: How knees fail...

- Early PUS

- Later Loosening



# Staphylococcus Aureus

80% of orthopaedic infections



Staphyl: bunch of grapes



Coccos: berry or grain



Aureus: golden coins



# Longer term outcomes matter too!

- 25% of Revisions for Total Joint Infection fail in by 5 years

- 35% of patients **dead** 5 years after joint infection




Fig. 1 Five-year survival rate comparing septic versus aseptic revision TJA.

COURTESY OF BRYAN D. SPRINGER, MD.




Fig. 2 Five-year survival rate for PJI and the five most commonly diagnosed (U.S.) cancers.

COURTESY OF JAVAD PARVIZI, MD, FRCS/ROTHMAN INSTITUTE AT THOMAS JEFFERSON UNIVERSITY

# Strong Evidence of Increased Infection



Home > All Guidelines > Management of Surgical Site Infections > Strong Evidence of Factors Associated with Increased Risk of SSI

**Strong evidence supports that the following factors are associated with an increased risk of infection:**

- Anemia
- Duration of Hospital Stay
- Immunosuppressive Medications
- History of Alcohol Abuse
- Obesity
- Depression
- History of Congestive Heart Failure
- Dementia
- HIV/AIDS

[Management of Surgical Site Infections](#)

Endorsed by: POSNA, AANA, APTA, MIS, OTA


★★★★ STRONG EVIDENCE



# Reoperations ~ ↑PUS

## Bleeding = Hematomas = Reoperations

Use of stronger anticoagulants have been associated with:  
 more bleeding/hematomas/wound ooze  
 more infections  
 less early ROM  
 no decrease in fatal PEs



**Most joint surgeons have gone to aspirin prophylaxis + compression**

(Cardiac patients on blood thinners have a higher rate of infection too...)

# Identify the bleeders

AAOS guidelines:

Ask about bleeding history/risks:

Hemophilia/Von Willebrand's disease

Liver disease



ISTH-SSC Bleeding Assessment Tool

<https://bleedingscore.certe.nl/>



Hemophilia A

# Identify the bleeders

Hold medicines that ↑ risk of bleeds

ASA – 10 days preop

NSAID – 5 ½ lives preop

Clopidrel/Prasugrel – 7days

Coumadin – 5 days preop

DOACs: Dabagatran – 4 days preop

Rivaroxaban – 3 days preop

Apixaban – 3 days preop

Hold “supplements”:

Garlic, Ginkgo, Ginseng,

Fish oil, Flax seed oil

Saw palmetto



# Anemia/Blood Loss/Transfusions

Preoperative anemia is common & usually treatable  
Preop Hgb **most significant predictor of transfusion**

Anemia common sign of other diseases  
(prevent colon cancer!)



TKA is a “high bleed risk” case

Blood loss is predictable

Transfusions are to be avoided:  
causes clinical problems and cost \$





QUANTIFICATION  
OF BLOOD LOSS



Trauma Mon. 2016 May; 21(2):e34131.

iron deficiency anemia




# Anemia: Identify and Treat

“THE MOST COMMON Blood Disorder”

- Iron deficiency ~ most common
- Vitamin deficiency ~ B12 and Folic acid
- Aplastic
- Hemolytic – autoimmune, mechanical

Point of service Hgb Test Screen  
Preop clinic testing

Anemia clinic vs anemia order set



# Anemia clinic flow


If HGB < 11 - 12 G/dL for primary TKA

Blood loss is predictable ~  
Average TKA Hgb drops: 3.85 +/- 1.4 G/dL

Transfusion Trigger ~ 7-8 G/dL

Medical team: Fe, vitamins  
Infusion Fe  
Infusion

Erythropoietin



# Transfusions: Risky and Costly

↑ periprosthetic infections – immunomodulatory effect

Linear increase per unit (Everhart JBJS 2018)

## Transfusion Reactions:

Allergic reaction 1:100

Fever or Urticaria 1:100

Non fatal hemolytic reaction 1:6,000

Fatal hemolytic reaction <1:600,000

Viral Infections:

HIV 1:2,000,000


HBV 1:100,000

HCV 1:1,600,000

HTLV,CMV 1:500 – 1:200,000

## Cost issues:

increased rehabilitation times  
lengthened hospital stays




# Avoid Transfusions: Avoid blood loss

Be prepared:  
Operate quickly and be technically brilliant...

Prepare patient for Spinal Anesthesia  
less blood loss

Use meds that limit bleeds





# Tranexamic acid:



↓ bleeding by inhibiting fibrinolytic system

cost effective: IV, Topical, or PO

safe ~ no increased DVT/PE in many large studies

Fibrinolytic system:  
ends in plasmin  
~ dissolves clots

- Mechanism of action:  
Lysine analog  
Binds plasminogen  
Inhibits fibrinolysis




# Cardiac Optimization

The most common cause of death = Cardiac  
The most common cause of death after TKA = Cardiac

13.5% arthroplasty patients had elevated cardiac troponin T POD#2

Delay surgery:  
6 mos after stenting  
6 mos after MI

If unable to do moderate functional capacity (4 MET) then invasive testing  
Light housework  
Climbing flight of stairs  
Walk up hill  
Walking 4 mph level



## CLINICAL PRACTICE GUIDELINE

2014 ACC/AHA Guideline on  
Perioperative Cardiovascular  
Evaluation and Management of  
Patients Undergoing Noncardiac Surgery

# Cardiac Optimization

## KNOW YOUR patient's CARDIAC MEDS!

Stopping Beta-blockers increases death  
**continue those -ol drugs!**  
twice as many DEATHS if you don't (ACC and AHA)

Continuing some can cause post-induction hypotension & AKI  
**STOP -il drugs (ACE inhibitors)**  
**STOP -sartan drugs (ARBs)**  
(Discuss with cardiology/medical team)



# Pulmonary Risk Assessment

## Pulmonary Risk Assessment.

### Risk Assessment

Current or past smoker >20 packets per y and PEFr <60%

Positive OSA screening (score 2 or more) (without prior Dx/treatment)

Pre-existing CPAP/BiPAP (need to use consistently min 2 wk pre-op)

Pulmonary hypertension (PAP >50) (non-cardiac)

Pulmonary fibrosis/ILD

History of asthma

History of COPD

Respiratory insufficiency (oxygen)

O<sub>2</sub> sat <90% on ABG

BMI >40 (if not already on OSA path)

If high then pulmonary complications prevention intervention protocol order set was started.

# Obstructive Sleep Apnea Tools

Screen: **STOPBANG**  
**Rothman OSA screen**  
**Mallampati Score**

**Sleep study prior to elective surgical procedures**  
**If apnea-hypopnea index > 20 then pulmonology consult**

The Mallampati Score



**CLASS I**  
 Complete visualization of the soft palate

**CLASS II**  
 Complete visualization of the uvula

**CLASS III**  
 Visualization of only the base of the uvula

**CLASS IV**  
 Soft palate is not visible at all

## STOP-BANG Scoring Method

Every Yes answer = 1 point

- S**noring: Do you snore loudly (loud enough to be heard through closed doors)?  Yes  No
- T**ired: Do you often feel tired, fatigued, or sleepy during daytime?  Yes  No
- O**bserved: Has anyone observed you stop breathing during your sleep?  Yes  No
- B**lood **P**ressure: Do you have or are you being treated for high blood pressure?  Yes  No
- B**MI more than 35?  Yes  No
- A**ge older than 50 years?  Yes  No
- N**eck circumference greater than 40 cm?  Yes  No
- G**ender male?  Yes  No

**5 or more = high risk for Obstructive Sleep Apnea**  
**Initiate or continue CPAP machine**  
**Avoid/minimize narcotics – maximize local blocks**

## Obstructive Sleep Apnea Screening.

Category	Score
<i>Loud snoring</i>	1
Neck circumference: male 17" or greater and female 16" or greater (if neck circumference not available, then BMI >35)	1
<i>Awakening with headaches</i>	1
<i>Witnessed apnea or awakening with choking/gasping</i>	2
<i>Morning or daytime sleepiness, especially if this interferes with ability to keep alert in situations where you should keep alert (driving, work, meetings)</i>	2
Mallampati class 4 oropharynx	1 (on examination)
Tonsillar hypertrophy (nearly touching)	2 (on examination)
<i>Prior diagnosis of sleep apnea which is not treated (ie, consistently using the CPAP or with proven effective alternate treatment)</i>	2

All patients were evaluated based on reported history or current symptoms of obstructive sleep apnea. If the score is 2 or higher, the patient was ordered a polysomnography. If the apnea-hypopnea index was higher than 20 in the mentioned study, the patient was referred for a pulmonary consultation. Italics, patient or family member reported. BMI, body mass index; CPAP, continuous positive airway pressure.

# Pulmonary Risk Protocol

## Interventions:

Smoking cessation  
 RX/optimize pulmonary dx  
 Perioperative Inhaler  
 Spinal anesthesia  
 Aspiration precautions:

resting bed > 20°  
 eating

bed > 45°  
 O2 sats at 92%  
 Incentive spirometry

## Results:

↓ pulmonary complication  
 rate

from 5.7% to .09%




## A Simple Protocol to Stratify Pulmonary Risk Reduces Complications After Total Joint Arthroplasty

Luis Grau, MD, Fabio R. Orozco, MD, Andres F. Duque, MD, MSc<sup>\*</sup>, Zachary D. Post, MD, Danielle Y. Ponzio, MD, Alvin C. Ong, MD

Department of Orthopaedic Surgery, Rothman Orthopaedics at Thomas Jefferson University, Egg Harbor Township, NJ

L. Grau et al. / The Journal of Arthroplasty 34 (2019) 1233–1239



# Diabetes

- Chronic issues of Diabetes Mellitus (Hgb A1C > 6.9)  
Small vessel disease:  
CAD, CVD, CRF, neuropathy

- Acute hyperglycemia:  
Collagen synthesis suppressed at 200 mg/dL  
**Impaired wound healing**

WBC phagocytosis impaired at 250 mg/dL  
**↓ ability to fight infection**



# Diabetes

- Postop complications more common:  
 UTI, Pneumonia, Anemia  
 Joint infections  
 Death
- **HGB-A1c < 7.5-8%**
- **NO glucose levels > 200mg/dL**  
**NO fasting glucose > 180mg/dL**

## A1C AND BLOOD GLUCOSE NORMAL, ELEVATED AND SEVERELY ELEVATED LEVEL CHARTS

SEVERELY ELEVATED	A1C LEVELS	GLUCOSE LEVELS
Levels. Risk of serious complications such as Heart Attack, Stroke, Blindness, Kidney failure, Amputations etc.	13	380
	12	345
	11	310
	10	275
ELEVATED and POORLY Controlled levels	9	240
	8	205
	* 7	170
NORMAL Levels	* 6	135
	5	100
	4	65

An A1C Diabetes test above **5.9** is considered Pre-Diabetic.

**Under 7** is considered normal or "GOOD" if you already have Diabetes.


Stay under **5.9** to play safe to avoid Prediabetes and under **7** if you already have a Diabetic.

If you are in Elevated or Severely Elevated Levels above, or getting close to **5.9** Prediabetics level, it is extremely important that you **Lose weight, Exercise,** and see a **Doctor and Nutritionist!**



# Bad Habits Smoking

- **Tissue Hypoxia:**  
Nicotine - microvascular vasoconstriction  
CO binds to HGB = carboxyhemoglobin
- ↓ bone, skin, soft tissue healing  
**Current smokers:**  
2x more TKA infections  
More readmissions (Tischler JBJS 2016)
- **Stopping: proven to decrease postop complications!**



## Smoking Increases the Rate of Reoperation for Infection within 90 Days After Primary Total Joint Arthroplasty

JBJS

**Conclusions:** This study, after controlling for confounding factors, demonstrated not only that current smokers have a significantly **increased risk of reoperation for infection within 90 days** of a surgical procedure compared with nonsmokers, but also that the amount that one has smoked, regardless of current smoking status, significantly contributed to **increased risk of nonoperative readmission.**

## Effect of Smoking Cessation Intervention on Results of Acute Fracture Surgery

JBJS

A Randomized Controlled Trial

**Conclusions:** Our results indicate that a smoking cessation intervention program during **the first six weeks after acute fracture surgery** decreases the risk of postoperative complications.

**Level of Evidence:** Therapeutic **Level I.** See Instructions to Authors for a complete description of levels of evidence.




# TEAM APPROACH: PERIOPERATIVE OPTIMIZATION FOR TOTAL JOINT ARTHROPLASTY

JBJS REVIEWS 2018;6(10):e4 · <http://dx.doi.org/10.2106/JBJS.RVW.17.00147>

- “HARD STOP” for smokers
- Help patients stop:  
Smoker cessation plan  
Trust but verify...
- Recommend  
6 weeks preop  
+ 6 weeks postop

## TOBACCO-FREE TOTAL JOINT ARTHROPLASTY: CONFIRMING TOBACCO CESSATION



### Smoking status definitions:

- **Never smoker:** has never used tobacco
- **Former smoker:** has not smoked within 1 year before date of surgery (document quit date and total pack years in Epic)
- **Active smoker:** current every-day smokers (document start date and current packs per day)
- **Recent smoker:** has been an every-day smoker within the past 1 year, but has quit within 1 week of surgery (document start & quit dates, and packs per day just prior to quitting)

### Explanation of "urine nicotine" tests:

- **Anabasine:** a breakdown molecule found only in tobacco products
- **Cotinine:** derivative of nicotine, found in both tobacco and nicotine replacement therapies (NRT) like the patch or gum

Fig. 3

Flowchart showing the tobacco cessation pathway. TJA = total joint arthroplasty, EMR = electronic medical record, NRT = nicotine replacement therapy, and PA = physician assistant.

# Bad habits: Alcohol ~ strong evidence ↑ pus

- Heavy ETOH:

[Blood ETOH] > 200mg/dl ~ **3x infections**  
↓ fibroblast production of collagen type I  
5 x higher risk of **postoperative bleeding**



- Cirrhosis ~ Liver failure 2-3x infection rate

Osteomalacia: ↓ 25 OH Vit D

MELD score >10 ~ higher surgical complications

- Malnutrition

- Bad behavior choices



# Bad habits: IVDA

## • NO DON'T DO IT


- All patients developed multiple re-infections after insertion of a drug-eluting spacer or THA (Ramczykowski ArOrthoTraSurg 2018)
- 10year failure rates 50%  
40% from septic failure  
wait 1 year "clean"  
verify with hair analysis (Wieser ArOrthoTraSurg 2012)
- Bugs in IVDA osteomyelitis:  
Staph Aureus ~ 50%  
Staph Epi ~ 20%  
Pseudomonas ~12%  
Anaerobes ~ 19%  
(> 50% polymicrobial)



Skin Popping Scars



# Bad Habits Screening process



HHS Publication No. SMA 15-4927

**Instruction:** Please check one box  for each question

	Three or more days in the past 12 months	One or two days in the past 12 months	Never in the past 12 months
In the <u>past 12 months</u> , on how many days did you use... <b>Tobacco?</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
In the <u>past 12 months</u> on how many days did you have... <b>4 or more alcoholic drinks in a day, including wine or beer?</b> <span style="border: 1px solid gray; border-radius: 50%; padding: 2px;">?</span>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
In the <u>past 12 months</u> on how many days did you use... <b>any Illegal Drug, including marijuana?</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
In the <u>past 12 months</u> on how many days did you use... <b>any Prescription Medications "recreationally" (just for the feeling, or using more than prescribed)?</b> <span style="border: 1px solid gray; border-radius: 50%; padding: 2px;">?</span>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

? Consider a "drink" to be a can or bottle of beer (12 ounces), a glass of wine (5 ounces), a wine cooler (12 ounces) or a shot of hard liquor like gin, vodka or whiskey (1.5 ounces).

"Recreationally" means taking medications just for the feeling or experience they cause, to get high, or taking them more often or at higher doses than prescribed. Prescription Medications are those that are prescribed to you or to someone else.



- Single needle stick: ~ 0.3% transmission
- Prophylactic antivirals after stick: 80%↓ transmission
- Most studies show ↑ rate of postop pus  
Hemophiliac studies – **high bleed ↑↑↑ risk**  
HIV from **IVDA ↑↑↑ risk**
- Modern studies (new drugs) only slight ↑  
if good [CD4] count and low viral load





Figure 7: HIV Prevalence and Incidence, 1980-2010



# Hepatitis C (Non A, Non B)

- Single stick transmission: ~ 2 - 3%
- WAS Most common transfusion-associated hepatitis
- Etiology US: 75% US patients **hx of IV drug use**  
2% from **health care occupation exposure**


NO VACCINE... ..now Rx ~ \$\$\$ Antivirals

- Cirrhosis, hepatocellular carcinoma

- 78% ↑ risk of a surgical complication
- 15% ↑ risk of postop medical complication (Issa JBJS 2015)

- ~2 times increase in TKA infections (Kidow 2018 JOA, Brown 2017 JAAOS)


- Preop Treatment may help:  
postoperative infections (15.5% vs 4.3% if Rx)  
surgical complications (21.1% vs 7.1% if Rx) (Schwarzkopf Bone Joint J. 2019)



Comparison of Postoperative Complications in Patients With Hepatitis C and Matched Control Patients Treated With Total Knee Arthroplasty




Complication	Patient Group		Statistical Comparison	
	No. With Hepatitis C <sup>a</sup> (%)	No. of Matched Controls <sup>b</sup> (%)	Odds Ratio (95% Confidence Interval)	P Value
Infection				
Within 3 mo	458 (3.0)	2,389 (1.6)	1.9 (1.7–2.0)	<0.0001
Within 6 mo	743 (4.8)	4,011 (2.7)	1.8 (1.7–2.0)	<0.0001
Within 1 yr	1,026 (6.7)	5,533 (3.8)	1.8 (1.7–2.0)	<0.0001
Aseptic revision total knee arthroplasty				
Within 6 mo	261 (1.7)	1,370 (0.9)	1.8 (1.6–2.1)	<0.0001
Within 1 yr	503 (3.3)	3,178 (2.2)	1.5 (1.4–1.7)	<0.0001
Within 2 yr	797 (5.2)	5,450 (3.7)	1.5 (1.3–1.5)	<0.0001
Up to 8 yr	1,152 (7.5)	8,081 (5.5)	1.4 (1.3–1.5)	<0.0001
Venous thromboembolism (3 mo)	235 (1.5)	2,045 (1.4)	1.1 (1.0–1.3)	0.198
Stiffness (3 mo)	185 (1.2)	1,974 (1.3)	0.9 (0.8–1.0)	0.147
Medical (3 mo)	901 (5.9)	5,909 (4.0)	1.5 (1.4–1.6)	<0.0001
Allogeneic blood transfusion (3 mo)	3,905 (25.4)	28,284 (19.3)	1.4 (1.4–1.5)	<0.0001

<sup>a</sup> Total number = 15,383  
<sup>b</sup> Total number = 146,541






Symmetrical joint space narrowing











Symmetrical joint space narrowing



Inflammatory Arthritides  
all have increased risks  
of infections!



# Biologic Agents ~ Anti-cytokine drugs

- TNF $\alpha$  blockers - etanercept (Enbrel) receptor fusion protein  
infliximab (Remicade) chimeric IgG  
adalimumab (Humira) monoclonal antibody
- IL-1 blockers - anakinra receptor antagonist
- IL-6 blocker - tocilizumab - anti-human IL-6 receptor antibody
- (B cells antibodies - (Rituxan) rituximab)
  
- Nomenclature: “-mab” monoclonal antibody (mAb)  
“-ximab” chimeric mAb (x cross species mouse+human)  
“-zumab” a humanized mAb  
“-cept” fusion of a receptor to the Fc part of human IgG1

•Very Effective!

•But many  $\uparrow$  risk of pus & atypical infections...

**-mab** = maybe you should stop them before surgery



# Immune System Drugs Guideline





AMERICAN COLLEGE  
OF RHEUMATOLOGY  
EDUCATION • TREATMENT • RESEARCH



<b>BIOLOGIC AGENTS: STOP</b> these medications prior to surgery and schedule surgery at the end of the dosing cycle. <b>RESUME</b> medications at minimum 14 days after surgery in the absence of wound healing problems, surgical site infection, or systemic infection.	<b>Dosing Interval</b>	<b>Schedule Surgery (relative to last biologic agent dose administered) during</b>
Adalimumab (Humira)	Weekly or every 2 weeks	Week 2 or 3
Etanercept (Enbrel)	Weekly or twice weekly	Week 2
Golimumab (Simponi)	Every 4 weeks (SQ) or every 8 weeks (IV)	Week 5 Week 9
Infliximab (Remicade)	Every 4, 6, or 8 weeks	Week 5, 7, or 9
Abatacept (Orencia)	Monthly (IV) or weekly (SQ)	Week 5 Week 2
Certolizumab (Cimzia)	Every 2 or 4 weeks	Week 3 or 5
Rituximab (Rituxan)	2 doses 2 weeks apart every 4-6 months	Month 7
Tocilizumab (Actemra)	Every week (SQ) or every 4 weeks (IV)	Week 2 Week 5
Anakinra (Kineret)	Daily	Day 2
Secukinumab (Cosentyx)	Every 4 weeks	Week 5
Ustekinumab (Stelara)	Every 12 weeks	Week 13
Belimumab (Benlysta)	Every 4 weeks	Week 5
Tofacitinib (Xeljanz): STOP this medication 7 days prior to surgery.	Daily or twice daily	7 days after last dose
<b>DMARDs: CONTINUE</b> these medications through surgery.	<b>Dosing Interval</b>	<b>Continue/Withhold</b>
Methotrexate	Weekly	Continue
Sulfasalazine	Once or twice daily	Continue
Hydroxychloroquine	Once or twice daily	Continue
Leflunomide (Arava)	Daily	Continue
Doxycycline	Daily	Continue

# Immune system drugs: Systemic Lupus Erythematosus



- If lupus is severe **continue drugs**  
nephritis, CNS, hemolytic anemia < 9,  
platelets < 50K, vasculitis, myocarditis,  
pneumonitis, enteritis, pancreatitis,  
cholecystitis, hepatitis, malabsorption  
protein-losing enteropathy,  
orbital inflammation/myositis,  
keratitis/uveitis/scleritis  
retinal vasculitis, optic neuritis

- If lupus is not severe **stop drugs**



AMERICAN COLLEGE  
OF RHEUMATOLOGY  
EDUCATION • TREATMENT • RESEARCH



AAHKS  
AMERICAN ASSOCIATION OF  
HIP AND KNEE SURGEONS

SEVERE SLE-SPECIFIC MEDICATIONS: CONTINUE these medications in the perioperative period.	Dosing Interval	Continue/Withhold
Mycophenolate mofetil	Twice daily	Continue
Azathioprine	Daily or twice daily	Continue
Cyclosporine	Twice daily	Continue
Tacrolimus	Twice daily (IV and PO)	Continue
NOT-SEVERE SLE: DISCONTINUE these medications 1 week prior to surgery	Dosing Interval	Continue/Withhold
Mycophenolate mofetil	Twice daily	Withhold
Azathioprine	Daily or twice daily	Withhold
Cyclosporine	Twice daily	Withhold
Tacrolimus	Twice daily (IV and PO)	Withhold

# Inflammatory Arthritides

## Biologic

- Rheumatology and AAHKS 2017 guidelines

DMARDs ~ continue

Biologics ~ **stop for the duration of dosing + 1 week**

restart ~14 days postop (after staples and healing)

Systemic Lupus: depends on if disease is severe

Longer term/higher dose prednisone bad

Guidelines favor NO stress doses – continue usual daily dose




# Optimization for RA

## Spinal block if able, but be prepared...

- NECK PAIN in ~ 25%
  - C1-C2 instability
  - Atlanto-Axial impaction
  - “Basilar invagination”

- Cricoarytenoid arthritis
  - Pain with speaking
  - Odynophagia
  - Hoarseness
  - Breathing difficulties




*If cervical symptoms,*

To avoid pithing...

**Be prepared!**

**Indirect laryngoscopy**



# Surgical Nutrition







# Malnutrition

- 40% of ortho patients are malnourished
- Up to 60% of elderly are malnourished

• Healing requires energy

• Risks:

- hematoma formation
- wound healing
- infection
- renal complications
- cardiac complications



# Malnutrition


## Measures of nutritional status

- History of weight loss:
  - > 10% over 6 months
  - > 5% over a month



- PE: BMI < 18.5

- Labs: Albumin < 3.0 – 3.5 g/dl  
Total Lymphocytes < 1,500/ml

Laboratory Parameter/Threshold for Malnutrition:	
Albumin	<3.5 g/dL
Prealbumin	<18 mg/dL
Total Protein	<6.0 g/dL
Total Lymphocyte Count	<1,500 Cells/mm <sup>3</sup>
Iron	<45 microg/dL
Serum Transferrin	<200 mg/dL
25-OH Vitamin D	<30 mg/dL
Calcium	<9 mg/dL
Zinc	<0.66 mcg/mL



## Human Serum Albumin




# Malnutrition Labs

Albumin < 3.0-3.5 g/dL

Transferrin <200 mg/dL

Total Lymphocytes: <1500/mm<sup>3</sup>

40-50% of patients with low values get poor wound healing &/or infection





# Obesity ~ a growing problem

2nd leading cause of preventable death in US (NIH)  
(first is smoking)

40% US prevalence of any obesity (BMI > 30)

Medical costs in US:  
~\$150 Billion/year  
~\$2000/year per person  
(Kim Value Health 2016)

Proportion of total joints done with BMI > 40 ↑



# Arthroplasty in Obesity

Improvements in pain and function (Mont JOA 1996, Baker JBJS 2012)

Challenging surgery

Increased complications

Wound healing

Infection higher in meta-analysis (Kerkhoffs JBJS 2012)


Deep infection: ~ 3-9 x higher. (Samson Anz J Surg 2010)

BMI>50 ~ 18x higher (Malinzak JOA 2009)

Revision rates

Increased in meta-analysis (Kerkhoffs JBJS 2012)

Increased x2 if >35 (Zingg Int Orth 2016)



# Obesity ~ sign of poor health

High BMI associated with:  
Less improvement in patient outcomes

Worse results/Higher Costs = lower value care

AAOS:  
“Accepted threshold for safe elective surgery is BMI < 40”


Home > All Guidelines > Surgical Management of Osteoarthritis of the Knee > BMI as A Risk Factor

Strong evidence supports that obese patients have less improvement in outcomes with total knee arthroplasty (TKA).

[Surgical Management of Osteoarthritis of the Knee](#)

Endorsed by: The Knee Society, SOMOS, AAHKS, ACR, AGS, AANA

★★★★ STRONG EVIDENCE



# Obesity pathways:

- “Teachable moment” to help individual and population health
- Preop considerations:
  - Nutritional status – often malnourished
  - Weight loss plan/Nutritional Counseling
  - Verbal/written contracts for weight loss goals
  - Bariatric Surgery?



# Obesity pathways:

- “Teachable moment” to help individual and population health
- Preop considerations:
  - Nutritional status – often malnourished
  - Weight loss plan/Nutritional Counseling
  - Verbal/written contracts for weight loss goals
  - Bariatric Surgery?





# Obesity pathways:

- BMI > 40 ~ “Hard stop” for elective cases at risk



The NEW ENGLAND  
JOURNAL of MEDICINE

ORIGINAL ARTICLE

## Weight and Metabolic Outcomes 12 Years after Gastric Bypass

Ted D. Adams, Ph.D., M.P.H., Lance E. Davidson, Ph.D., Sheldon E. Litwin, M.D., Jaewhan Kim, Ph.D., Ronette L. Kolotkin, Ph.D., M. Nazeem Nanjee, Ph.D., Jonathan M. Gutierrez, B.S., Sara J. Frogley, M.B.A., Anna R. Ibele, M.D., Eliot A. Brinton, M.D., Paul N. Hopkins, M.D., M.S.P.H., Rodrick McKinlay, M.D., *et al.*




- Multiple National Guidelines:  
consider bariatric surgery if:  
**BMI>35 with co-morbidities**  
**BMI>40**



American Association of  
Clinical Endocrinologists



American  
Heart  
Association®




# Bariatric Surgery


Not just improving BMI  
But often curing diabetes!

Lowering overall health care costs.

Body-Mass Index



Glycated Hemoglobin



# TKA and THA after Bariatric surgery

Retrospective Review 2006-2014  
530,160 THA patients and 1,113,116 TKA patients  
2006-2014 Nationwide Inpatient Sample  
(All patients, all payers of 20% of US community hospitals)

Arthroplasty after Bariatric surgery vs Morbid obesity (BMI>40)  
Comorbidity matched  
In house complications only

THA ~ fewer PE  
shorter length of stay

TKA ~ fewer PE & respiratory complications  
shorter length of stay  
fewer deaths

↑ risk of anemia & transfusion



Impact of Bariatric Surgery on Inpatient Complication, Cost, and Length of Stay Following Total Hip or Knee Arthroplasty

Yicun Wang, PhD<sup>a</sup>, Zhantao Deng, PhD<sup>b</sup>, Jia Meng, PhD<sup>a</sup>, Qiying Dai, MD<sup>c</sup>,  
Tao Chen, PhD<sup>d</sup>, Nirong Bao, MD, PhD<sup>a,\*</sup>

# TKA and THA after Bariatric surgery



Bariatric Surgery Improves Outcomes After Lower Extremity Arthroplasty in the Morbidly Obese: A Propensity Score-Matched Analysis of a New York Statewide Database

Alexander S. McLawhorn, MD, MBA <sup>a,\*</sup>, Ashley E. Levack, MD, MAS <sup>a</sup>, Yuo-yu Lee, MS <sup>b</sup>, Yile Ge, MS <sup>b</sup>, Huang Do, MA <sup>b</sup>, Emily R. Dodwell, MD, MPH <sup>a</sup>

Bariatric surgery prior to TJA  
reduced co-morbidity burden at the time of  
TJA reduced post-TJA complications

However, *did not* reduce the risk for revision

# TKA and THA after Bariatric surgery




Bariatric Surgery Improves Outcomes After Lower Extremity Arthroplasty in the Morbidly Obese: A Propensity Score-Matched Analysis of a New York Statewide Database

Alexander S. McLawhorn, MD, MBA <sup>a,\*</sup>, Ashley E. Levack, MD, MAS <sup>a</sup>, Yuo-yu Lee, MS <sup>b</sup>, Yile Ge, MS <sup>b</sup>, Huong Do, MA <sup>b</sup>, Emily R. Dodwell, MD, MPH <sup>a</sup>

Bariatric surgery prior to TJA  
reduced co-morbidity burden at the time of  
TJA reduced post-TJA complications

However, **did not** reduce the risk for revision

Consider bariatric consult  
at first arthritis visit!



**Optimization**

**HOW  
DOES IT  
WORK**



# National Consultants

Well oiled programs claim:

Lower costs for hospital

Decreased readmissions

## Sg2 Client Results

### Organizations have gained:

Internal cost savings of **10% to 30%**  
with implementation of gainsharing programs.

Medicare spend improvement from  
**5% to 20%** through reductions in  
post-acute care utilization and readmissions.

Data-driven analyses to determine which  
episodes to include and which payers to  
approach for commercial bundles.

**\$40 million**  
of annualized NPRA  
and ICS

ICS = internal cost savings; NPRA = net payment reconciliation amount.


# UC Irvine ~ lower costs

## “Perioperative Surgical Home”

California Private Insurers set cap ~\$30K

Benchmark TKA ~ \$17,588 + implants

UC Irvine costs ~ \$10K + implants



**Table 5 Benchmark cost comparison: average hospital cost excluding implants<sup>a</sup>**

	Total Joint-PSH	Benchmark [16]
TKA	\$10,042 ± 1,305	\$17,588
THA	\$9952 ± 1,294	\$16,267

PSH, perioperative surgical home; THA, total hip arthroplasty; TKA, total knee arthroplasty.

<sup>a</sup>Data are expressed as mean ± SD.



# “Infection Reduction Committee” At one hospital

Rothman Institute  
Decreased infections from 1% to  
.4%

*L.J. Matsen Ko et al / The Journal of Arthroplasty 31 (2016) 451-455*




Fig. 1. Timeline for implementation of IRC recommendations



Contents lists available at ScienceDirect

The Journal of Arthroplasty

journal homepage: [www.arthroplastyjournal.org](http://www.arthroplastyjournal.org)

## The Effect of Implementing a Multimodal Approach on the Rates of Periprosthetic Joint Infection After Total Joint Arthroplasty

Laura J. Matsen Ko, MD, Joanne Y. Yoo, BS, Mitchell Maltenfort, PhD, Amy Hughes, RN, Eric B. Smith, MD, Peter F. Sharkey, MD

The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania

### ABSTRACT

**Introduction:** We examined the efficacy of implementing a multimodal program aimed at reducing the incidence of periprosthetic joint infection (PJI) after total joint arthroplasty (TJA) in a mid-size community hospital.

**Methods:** An infection reduction committee (IRC) was formed at our hospital in November 2010. The IRC consisted of two orthopaedic surgeons, an infectious disease specialist, an internist with extensive experience in perioperative medical management of TJA patients, an anesthesiologist, the hospital infection control nurse, and two additional nurses. Their goals were to 1) evaluate the current incidence of PJI at our institution, compare it with the reported national data, and consider measures already in place directed at preventing PJI; 2) review and routinely evaluate recently published studies or information obtained from continuing medical education events related to PJI to determine if practice changes were warranted (based on intervention efficacy, cost, and safety) and then develop a plan to implement appropriate alterations in perioperative protocols using a multimodal strategy; and 3) evaluate the effect and safety of newly-introduced infection reduction strategies on the incidence of PJI.

**Results:** In 2008, the incidence of PJI at our hospital was 1.0%. By 2013, this rate had reduced to 0.4%. In absolute numbers, in 2009, 20 of 1,150 TJAs developed a PJI in the 12-month period following partial, primary, or revision TJA. In 2013, PJI occurred in only 4 of 1,053 TJA patients.

**Conclusion:** We found that formation of an IRC focused on evaluating and implementing strategies to reduce PJI following TJA can be effective.

# Veterans Hospital

## 2017 JOA

- VA population with 2 year f/u
- Screens: BMI  $\leq$  35  
HgbA1C  $\leq$  7  
Alb  $\geq$  3.5  
HGB  $\geq$  11


- Results:

↓ SSI (by MSIS): 4% vs 1%


↓ Total complications: 35% vs 15%

- ~ intra-op, return to OR, readmits < 90 days
- ~ SSI (deep and superficial)
- ~ transfusion, pressure ulcers, UTIs
- ~ DVT/PE, MI and death

### Complication Rates Pre Vs. Post Screening Implementation



### SSI Rates Pre Vs. Post Screening Implementation



# Duke PASS clinic Did **NOT** pass!

2019 JOA


Multiple hospitals in a system  
Some participating in bundles  
Some not

Some improvement in the # of “violations”  
(failure to follow their own process)


No improvement in Readmissions

May depend on  
how strict rules of optimization are followed  
how low readmissions were before

- Risk Stratification Checklist for Total Joint Replacement**
- BMI  $\geq 40$  kg/m<sup>2</sup>
  - Active smoking
  - HgA1C  $>7.5\%$
  - Albumin  $\leq 3$  g/dL
  - Hemoglobin  $< 11$  g/dL
  - Thrombocytopenia (platelets  $< 50K/L$ )
  - ESRD on Dialysis
  - CAD (with or without AMI in past 6 months)
  - Stroke or TIA within past 6 months
  - Active infections
  - Chronic narcotics use (addiction)



Percentage 90-day Readmissions vs List Violations Over Time





## Total joint results at Large multi-specialty Practice (Missouri)


**1/3 less infections**  
**25% less readmissions**

Metric	Percentage Reduction (from baseline)*
90-day Readmission Rate	26%
30-day Readmission Rate	28%
Pulmonary Embolism during Index Admission	72%
Surgical Site Infection	37%
DVT During Index Admission	51%
UTI During Acute Admission	41%
Acute MI within 7 days post surgery	23%

\* Results generated by Signature Medical Group from Medicare claims data.


# NQF Endorsed Quality Measure For THA/TKA CMS Medicare data national “overall effect” **Risk-Standardized** Readmission Rate (RSRR)

- 2012 5.7%
- 2019 ~4%



## 2019 Procedure-Specific Readmission Measures Updates and Specifications Report

Figure 4.3.2 – Distribution of Hospital 30-Day THA/TKA RSRRs between July 2015 and June 2018




**Optimization: not a destination but a work in progress:**

**Value based programs only growing in number of participants and programs.**

Folly is rewarding A, while hoping for B

*Steven Kerr, PhD  
Organizational Behavior Expert*

**Focus On Creating the Desired Culture**



The best reward in  
medicine is to get paid  
to make a difference!



It's easy to make a buck.  
It's a lot tougher to  
**MAKE A DIFFERENCE**







## **Perioperative Orthopedic Surgical Home (POSH)**

**S Aureus colonization**

**Neurocognitive**


**Psychological and behavioral problems**

**Catastrophizing avoidance**

**Fall education prevention**

**Physical deconditioning Frailty assessment**

## PERIOPERATIVE SURGICAL HOME – ENHANCED RECOVERY AFTER SURGERY



### Pre-surgical

- Indication
- Optimization
- Education

### Periop

- Day of surgery prep
- Premedication

### Postop

### Postdischarge

## Why MACRA – Metrics

Cost  
Quality

## Bundles – for THA and TKA

Comprehensive Care for Joint Replacement.  
Financial accountability  
BUT share savings if quality measures

## MACRA:

MIPS – incentive for quality & costs  
ACO ~ Accountable Care Organization  
Financial risk with quality metrics

Optimization: change the way we practice

One for you , two for me.....



# Guidelines to prevent PUS



Centers for Disease Control and Prevention  
 CDC 24/7: Saving Lives, Protecting People™

## Centers for Disease Control 2017 Guidelines for Prevention of Surgical Site Infection

Core Section	Relevant Recommendations
Parenteral Antimicrobial Prophylaxis	<ul style="list-style-type: none"> <li>Administer preoperative antimicrobial agents only when indicated; timed such that serum/tissue bactericidal concentration is established prior to incision</li> <li>Weight-adjusted dosing – No literature to support effects on risk of SSI</li> <li>Do not administer additional antibiotics after surgical incision is closed for clean/clean-contaminated procedures</li> </ul>
Nonparenteral Antimicrobial Prophylaxis	<ul style="list-style-type: none"> <li>Do not apply antimicrobial agents to surgical incision</li> <li>Application autologous platelet-rich plasma not necessary</li> <li>Antimicrobial dressings applied to surgical incision after primary closure</li> </ul>
Glycemic Control	<ul style="list-style-type: none"> <li>Implement perioperative glycemic control; blood glucose target &lt; 200 mg/dL</li> <li>Optimal HbA1C target</li> </ul>
Normothermia	<ul style="list-style-type: none"> <li>Maintain perioperative normothermia</li> </ul>
Oxygenation	<ul style="list-style-type: none"> <li>Administer increased fraction of inspired oxygen during surgery and immediate postoperative period to optimize tissue oxygen delivery, maintain perioperative normothermia and adequate volume replacement (normal pulmonary function)</li> </ul>
Antiseptic Prophylaxis	<ul style="list-style-type: none"> <li>Advise patients to shower/bathe with soap or antiseptic agent on at least the night before operative day</li> <li>Application microbial sealant after intraoperative skin preparation not necessary</li> <li>Consider intraoperative irrigation of deep or subcutaneous tissues with aqueous iodophor solution</li> </ul>
Blood Transfusion	<ul style="list-style-type: none"> <li>Do not withhold transfusion of necessary blood products from surgical patients as a means to prevent SSI</li> </ul>
Systemic Immunosuppressive Therapy	<ul style="list-style-type: none"> <li>Available evidence suggests uncertain trade-offs between benefits and harms of systemic corticosteroid or immunosuppressive therapies on risk of SSI</li> </ul>
Intra-articular Corticosteroid Injection	<ul style="list-style-type: none"> <li>Available evidence suggests uncertain trade-offs between benefits and harms of use and timing of perioperative intra-articular corticosteroid injection on SSI</li> </ul>
Anticoagulation	<ul style="list-style-type: none"> <li>Available evidence suggests uncertain trade-offs between benefits and harms of venous thromboembolism prophylaxis on incidence of SSI</li> </ul>
Orthopaedic Surgical Space Suit	<ul style="list-style-type: none"> <li>Available evidence suggests uncertain trade-offs between benefits and harms of orthopaedic space suits or the healthcare personnel who should wear them</li> </ul>
Drain Use	<ul style="list-style-type: none"> <li>Do not administer additional antibiotics after surgical incision is closed in presence of a drain</li> </ul>
Biofilm	<ul style="list-style-type: none"> <li>Prosthesis modifications or usage of biofilm control agents; dispersants quorum sensing inhibitors novel antimicrobial agents for prevention of biofilm formation or SSI</li> </ul>

# Cost and Quality Combined for profit = Bundle

Qualitative and quantitative analysis to drive episode recommendations:



## Sg2 Client Results

Organizations have gained:

Internal cost savings of **10% to 30%** with implementation of gainsharing programs.

Medicare spend improvement from **5% to 20%** through reductions in post-acute care utilization and readmissions.

Data-driven analyses to determine which episodes to include and which payers to approach for commercial bundles.

**\$40 million** of annualized NPRA and ICS

ICS = internal cost savings; NPRA = net payment reconciliation amount

## BPCI Advanced Analyzation



**Sg2 Experience:** Three decades of bundled payment experience; 9 Medicare BP Programs, 100+ physician sharing arrangements; support of 170+ EIs in BPCI, CJR, BPCI Advanced

## Bundled Payments Keys to Success



## Target Pricing Will Incorporate Multiple

Target prices will be provided prospectively for each episode at an acute care hospital. Three major components make up the target price episode at an acute care hospital:

$$HBP = SBS * PCMA * P$$



# Healthcare Quality Model

## Donabedian 1966

